🔴 Tvardi Therapeutics is trading 9.6% down in after-hours trading

Tvardi Therapeutics is trading at $1.13, down 9.60% in after-hours trading, with no clear company-specific catalyst identified.

• The regular-session close was $1.25, following declines in each of the prior two sessions.
• The latest located company announcement was September 24 preclinical research on STAT3 inhibitors in ulcerative colitis, not a new after-hours announcement.
• Provided market context is mixed and does not establish a broad-market explanation for the September 30, 2026 move.